MedTrace Logo

The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory

NCT07164430 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2792

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this observational study is to is to examine the impact of new RSV prevention medicines on the burden of RSV disease among young children. The main question it aims to answer is:

What was the impact of the 2025 RSV prevention program on RSV-related hospitalisation in children under 2 years of age?

Participants won't need to do anything additional for the study as only routinely collected health information will be used to answer the research question.

Conditions

  • Respiratory Syncytial Virus (RSV) Infection
  • Respiratory Syncytial Virus Hospitalizations
  • Respiratory Syncytial Virus Immunization

Sponsors & Collaborators

  • Kirby Institute

    collaborator OTHER_GOV

  • The University of New South Wales

    collaborator OTHER

  • Nicola Irwin

    lead OTHER

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07164430 on ClinicalTrials.gov